Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5340855 | 0.90 | TSHR (0.68) | CREBBPLMNATSHRHSD17B10 | |
| SCHEMBL6196393 | 0.87 | PTPN11 (0.57) | CREBBPAKR1C3AKR1C2HDAC8HDAC1 | |
| SCHEMBL5874111 | 0.87 | CREBBP (0.67) | CREBBPLMNATSHRHSD17B10CYP3A4 | |
| SCHEMBL17395803 | 0.87 | CREBBP (0.76) | CREBBPHDAC8HDAC1HDAC6BRD4 | |
| SCHEMBL6200527 | 0.86 | PTPN11 (0.63) | CREBBPTSHRAKR1C3AKR1C2HDAC8 | |
| SCHEMBL13528549 | 0.85 | AKR1C3 (0.51) | CREBBPAKR1C3AKR1C2 | |
| SCHEMBL7962680 | 0.85 | CREBBP (0.62) | CREBBPTSHRHSD17B10HDAC8HDAC1 | |
| SCHEMBL7566116 | 0.85 | PTGDR2 (0.63) | CREBBPAKR1C3AKR1C2 | |
| SCHEMBL5151569 | 0.84 | PTPN11 (0.65) | CREBBPLMNAHDAC8HDAC1HDAC6 | |
| SCHEMBL5334076 | 0.84 | LMNA (0.54) | CREBBPLMNATSHRHSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379491-B1 | Process for synthesis of amino-methyl tetraline derivatives | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | claimed |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | DURKIN KIERAN (US) | 2012-12-20 | — | — | US | claimed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | claimed |
| EP-2379491-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | claimed |
| WO-2010069778-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | claimed |
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | claimed |
| CN-116135892-A | Method for preparing bimodal polyethylene resin for pipe material and bimodal polyethylene resin thereof | 中国石油化工股份有限公司 | 2023-05-19 | — | — | CN | disclosed |
| WO-2016001452-A1 | COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED | Universität Zürich (CH) | 2016-01-07 | — | — | WO | disclosed |
| US-9108915-B2 | Method for producing 3,4-disubstituted pyrrolidine derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| EP-2634172-A1 | METHOD FOR PRODUCING 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217893-A1 | METHOD FOR PRODUCING 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-8119630-B2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20100015717-A1 | Mass Tags for Quantitive Analysis | PPD BIOMARKER DISCOVERY SCIENCES LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-5482941-A | Quinazolinone antianginal agents | PFIZER INC. (US) | 1996-01-09 | — | — | US | disclosed |
| US-5426107-A | Treatment of cardiovascular disorders, asthma, allergies | PFIZER INC. (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0628032-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | Pfizer Limited (GB) | 1994-12-14 | — | — | EP | disclosed |
| US-5272147-A | Pyrazolopyrimidinone antianginal agents | PFIZER INC. (US) | 1993-12-21 | — | — | US | disclosed |
| WO-1993012095-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-06-24 | — | — | WO | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
| CN-1068329-A | Pyrazolopyrimidinoneantianginal antianginal agents | PFIZER (US) | 1993-01-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | PKN2, CCND2, PRMT1 | CREBBP 4557/4885LMNA 2118/4885TSHR 1800/4885 |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | PKN2, CCND2, PRMT1 | CREBBP 4566/4885LMNA 2171/4885TSHR 1861/4885 |
| US-20130217893-A1 | METHOD FOR PRODUCING 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE | PTGS1, PTGER1, HPD | CREBBP 4118/4885LMNA 3437/4885TSHR 2774/4885 |
| US-20100015717-A1 | Mass Tags for Quantitive Analysis | PTMS, CHAMP1, TMT1A | CREBBP 1395/4885LMNA 3920/4885TSHR 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.